{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114582","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.804815+00:00","generated_at":"2026-06-08T21:26:24.984616+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Barinthus Biotherapeutics (fka Vaccitech) begins trading under BRNS, presents Phase 2 HBV data","bullets":["Company renamed to Barinthus Biotherapeutics; Nasdaq ticker changes from VACC to BRNS effective Nov 7, 2023.","Phase 2 hepatitis B trial data for VTP-300 to be presented at AASLD Liver Meeting Nov 10-14, including combination with imdusiran.","Shareholders approved resolutions authorizing directors to allot shares up to £1,928 nominal and disapply pre-emption rights.","Strategic shift from vaccines to T cell immunotherapies targeting chronic infectious diseases, autoimmunity, and cancer.","Clinical collaboration with Arbutus Biopharma highlighted in late-breaking abstract on VTP-300 plus imdusiran."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114582","json":"https://secwatch.observer/filing/0001104659-23-114582.json","markdown":"https://secwatch.observer/filing/0001104659-23-114582.md","text":"https://secwatch.observer/filing/0001104659-23-114582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/0001104659-23-114582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/tm2329836d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:26:24.984616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f8fd5530fe223305d38aa4783bf0612e4fdec5","claim":"Barinthus Biotherapeutics plc. shareholders approved Disapplication of pre-emption rights (Special Resolution) at the 2023-11-06 meeting.","evidence_excerpt":"For Against Withheld Broker Non-Votes THAT, conditional upon Resolution 1 above being duly passed, the directors of the Company or any duly authorized committee of the directors be generally empowered pursuant to section 570 of the U.K. Companies Act 2006 to allot equity securities (within the meaning of the U.K. Companies Act 2006) for cash pursuant to the authority conferred on them by Resolution 1 as if section 561 of the U.K. Companies Act 2006 and any pre-emption provisions in the articles of association of the Company (or howsoever otherwise arising) did not apply to the allotment for a period expiring (unless previously renewed, varied or revoked by the Company prior to or on that date) five years after the date on which this Resolution is passed save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted after such expiry and the directors may allot shares in pursuance of any such offer or agreement notwithstandin","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/0001104659-23-114582-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-06"}],"fact_type":"shareholder_vote"},{"claim_id":"9d5e7ebd1bc51e11937fea6b1db79435364f25b7","claim":"Barinthus Biotherapeutics plc. shareholders approved Authorization to allot shares (Ordinary Resolution) at the 2023-11-06 meeting.","evidence_excerpt":"For Against Withheld Broker Non-Votes THAT, in accordance with section 551 of the U.K. Companies Act 2006, the directors of the Company or any duly authorized committee of the directors be generally and unconditionally authorized to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of £1,928 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) five years after the date on which this Resolution is passed, save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or Rights to be granted and the directors may allot shares or grant Rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this Resolution has expired. The authority referred to in this Resolution is in addition to all subsisting authorities conferred on the director","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/0001104659-23-114582-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}